authors.affiliation: 1 Abteilung für Hämatologie und Hämatologisches Zentrallabor, Luzerner Kantonsspital.
authors.forename: Lucas
authors.initials: L
authors.lastname: Simeon
authors.affiliation: 1 Abteilung für Hämatologie und Hämatologisches Zentrallabor, Luzerner Kantonsspital.|2 Universität Bern.
authors.forename: Walter A
authors.initials: WA
authors.lastname: Wuillemin
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000931:Antidotes / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy; D000069604:Dabigatran / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D008657:Metabolic Clearance Rate / Q000502:physiology; D011247:Pregnancy; D011720:Pyrazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011728:Pyridones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069552:Rivaroxaban / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D020521:Stroke / Q000097:blood / Q000517:prevention & control*; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000931:Antidotes; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban